Hemab Therapeutics Holdings, Inc. Operating Expenses
Hemab Therapeutics Holdings, Inc. (COAG) reported Operating Expenses of $26.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Hemab Therapeutics Holdings, Inc. operating expenses for the quarter ending 2026-06-30 was $26.08M, a 62.42% increase year-over-year.
- Hemab Therapeutics Holdings, Inc. operating expenses for the quarter ending 2026-03-31 was $23.61M, a 42.58% increase year-over-year.
- Hemab Therapeutics Holdings, Inc. operating expenses for the quarter ending 2025-06-30 was $16.06M.
- Hemab Therapeutics Holdings, Inc. operating expenses for the quarter ending 2025-03-31 was $16.56M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month |
|---|---|---|
| 2026-06-30 | $26.08M 10-Q · filed 2026-08-11 | $49.69M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $23.61M 10-Q · filed 2026-05-21 | |
| 2025-06-30 | $16.06M 10-Q · filed 2026-08-11 | $32.62M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $16.56M 10-Q · filed 2026-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |